PFS
ZNTL icon

Prospera Financial Services’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Prospera Financial Services’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-48,780
Closed -$200K – 1204
2024
Q2 		$200K Buy
48,780
+24,745
+103% +$276K 0.01% 1073
2024
Q1 		$379K Buy
24,035
+5,733
+31% +$78.9K 0.01% 807
2023
Q4 		$277K Buy
+18,302
New +$267K 0.01% 880
2022
Q3 		– Sell
-89
Closed -$2K – 1615
2022
Q2 		$2K Sell
89
-2,161
-96% -$57.2K ﹤0.01% 1578
2022
Q1 		$104K Buy
+2,250
New +$121K ﹤0.01% 1101

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Prospera Financial Services's ZNTL Position: Q3 2024 in Review

Prospera Financial Services sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 48,780 shares — an estimated $200K sold.

Prospera Financial Services first reported a position in ZNTL in Q1 2022 and held it in 5 quarters. The position peaked at $379K in Q1 2024. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • Prospera Financial Services reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Prospera Financial Services sold 48,780 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $200K.
  • Prospera Financial Services first reported a position in Zentalis Pharmaceuticals in Q1 2022 and held it in 5 quarters.
  • Prospera Financial Services's Zentalis Pharmaceuticals position peaked at $379K in Q1 2024.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Prospera Financial Services's 13F filing for Q3 2024, filed 7 Nov 2024.